A role of the tuberous sclerosis gene-2 product during neuronal differentiation.
Tuberous sclerosis is an autosomal dominant disorder. Besides the development of benign growths (hamartomas) in different tissues, one hallmark of this disease is the presence of highly epileptogenic dysplastic lesions in the cerebral cortex (tubers) composed of abnormal shaped neurones. Patients often show evidence of severe mental retardation. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16. The TSC2 gene on chromosome 16 encodes a 1784-amino acid putative tumour suppressor protein, tuberin, that functions as a GTPase-activating protein. Here we show that tuberin expression is upregulated upon induction of neuronal differentiation in the neuroblastoma cell lines SK-N-SH and LAN-1. This upregulation occurs at post-transcriptional level and is independent of the proliferation status. TSC2 expression is unaffected during differentiation of C2C12 myoblasts into myotubes and of F9 embryonal carcinoma cells into cells resembling parietal endoderm. Antisense inhibition of tuberin expression in SK-N-SH or LAN-1 cells inhibits neuronal differentiation, but does not affect the differentiation of F9 cells. Ectopic overexpression of TSC2 not only reverts the antisense-associated phenotype but furthermore accelerates the neuronal differentiation process. Our data show for the first time that tuberin plays a critical role in neuronal differentiation. Such role is consistent with the phenotype of tuberous sclerosis patients, who inherit one defective TSC2 allele, and frequently lose the remaining normal allele in many of the tubers/hamartomas which develop in the central nervous system of these patients.
Soucek
T
T
Obstetrics and Gynecology, University of Vienna, Department of Prenatal Diagnosis and Therapy, Austria.
Hölzl
G
G
Bernaschek
G
G
Hengstschläger
M
M
D000818:Animals; D018236:Carcinoma, Embryonal / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D006801:Humans; D051379:Mice; D009447:Neuroblastoma; D009474:Neurons / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D012097:Repressor Proteins / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology*; D014162:Transfection; D014212:Tretinoin / Q000494:pharmacology; D014402:Tuberous Sclerosis / Q000235:genetics* / Q000473:pathology; D000077005:Tuberous Sclerosis Complex 2 Protein; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins
D016376:Oligonucleotides, Antisense; D012097:Repressor Proteins; C000624653:TSC2 protein, human; C000624654:Tsc2 protein, mouse; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; D014212:Tretinoin